WALTHAM, Mass., Sept. 5, 2018 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:
SNDX), a clinical stage biopharmaceutical company developing an
innovative pipeline of cancer therapies, today announced that data
from the PD-(L)1 refractory non-small cell lung cancer (NSCLC)
cohort of ENCORE 601 will be presented at the upcoming
International Association for the Study of Lung Cancer (IASLC) 19th
World Conference on Lung Cancer (WCLC) being held September 23-26, 2018 in Toronto, Canada. ENCORE 601 is a Phase
1b/2 trial evaluating the efficacy
and safety of entinostat, the Company's class I selective HDAC
inhibitor, in combination with KEYTRUDA®
(pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1)
therapy, across multiple cohorts of PD-(L)1 treatment-naïve and
pre-treated cancers, including NSCLC, melanoma and microsatellite
stable colorectal cancer.
The accepted abstract is available on the World Conference on
Lung Cancer website at https://wclc2018.iaslc.org/. Updated data
will be presented at the conference.
Presentation Details
Title: Efficacy/Safety of Entinostat (ENT) and
Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with
Anti-PD-(L)1 Therapy
Presenter: Matthew D.
Hellmann, M.D., Memorial Sloan Kettering Cancer Center
Track: Advanced NSCLC
Session: OA05 - Clinical Trials in IO
Presentation Number: OA05.01
Date and Time: September 24, 2018 1:30 - 1:40 PM ET
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies. The Company is developing its lead product
candidate, entinostat, a once-weekly, oral, small molecule, class I
HDAC inhibitor, in combination with exemestane and several approved
PD-1/PD-L1 antagonists. The Company's pipeline also includes
SNDX-6352, a monoclonal antibody that blocks the colony stimulating
factor 1 (CSF-1) receptor, as well as a portfolio of potent and
selective inhibitors targeting the binding interaction of Menin
with MLLr. For more information, please
visit www.syndax.com or follow the Company
on Twitter and LinkedIn.
Syndax's Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend," "believe" and similar expressions (as well as
other words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Syndax's expectations
and assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. Forward-looking statements contained in this press
release include, but are not limited to, statements about the
progress, timing, clinical development and scope of clinical trials
and the reporting of clinical data for Syndax's product candidates,
and the potential use of our product candidates to treat various
cancer indications. Many factors may cause differences between
current expectations and actual results including unexpected safety
or efficacy data observed during preclinical or clinical studies,
clinical trial site activation or enrollment rates that are lower
than expected, changes in expected or existing competition, changes
in the regulatory environment, failure of Syndax's collaborators to
support or advance collaborations or product candidates and
unexpected litigation or other disputes. Other factors that may
cause Syndax's actual results to differ from those expressed or
implied in the forward-looking statements in this press release are
discussed in Syndax's filings with the U.S. Securities and
Exchange Commission, including the "Risk Factors" sections
contained therein. Except as required by law, Syndax assumes no
obligation to update any forward-looking statements contained
herein to reflect any change in expectations, even as new
information becomes available.
Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
Tel 212.600.1902
SNDX-G
View original
content:http://www.prnewswire.com/news-releases/syndax-to-present-at-the-international-association-for-the-study-of-lung-cancer-19th-world-conference-on-lung-cancer-300707526.html
SOURCE Syndax Pharmaceuticals, Inc.